Dr. Scherber Discusses Ruxolitinib Failure In Myelofibrosis

Dr. Scherber Discusses Ruxolitinib Failure in Myelofibrosis

Dr. Scherber on the Treatment of Myelofibrosis

Management of ruxolitinib failure in myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Discussing Options for Ruxolitinib-Refractory Patients With Myelofibrosis

Targeted Oncology

Phase I study of ruxolitinib plus abemaciclib for patients with myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Dr Prithviraj Bose Discusses Identifying Progression in Myelofibrosis

Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis

Myelofibrosis: Long-Term Survival Data and Ruxolitinib Use

Targeted Oncology

Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in Myelofibrosis

Maureen E. Thyne Discusses Ruxolitinib's Impact on Myelofibrosis

Real-world use of ruxolitinib in patients with myelofibrosis with anemia or thrombocytopenia

VJHemOnc – Video Journal of Hematology & HemOnc

Managing patients with high-risk myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

MANIFEST: pelabresib in combination with ruxolitinib in myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Snyder Discusses Emerging Agents in Myelofibrosis

Ruxolitinib combinations in patients with myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

JAKARTA2 update: fedratinib in MF patients previously treated with ruxolitinib

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Ruben Mesa Discusses the COMFORT Ruxolitinib Trials

Dr. Verstovsek on Accelerated Phase Myelofibrosis